Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Aurigene Discovery Technologies Ltd

    Aurigene is a specialized biotech company, focused on oncology and inflammatory diseases. Aurigene has deep target and therapeutic area expertise, gained from the experience of

  • No Image
    Auro Laboratories Ltd

    Auro Laboratories is a manufacturer of Active Pharmaceutical Ingredients (API's), Intermediates and Generic Formulations. Auro Laboratories was founded and incorporated in 1992

  • No Image
    Aurobindo Pharma Ltd

    Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company co

  • No Image
    Avanscure Lifesciences Pvt Ltd

    Avanscure LifeSciences Pvt. Ltd. is engaged in the active manufacture of pharmaceutical ingredients (APIs), formulations, biological products, chemicals, and intermediates. Thei

  • No Image
    Avaya Industries Ltd

    Incorporated in 2010, Avaya Industries Ltd (AIL) is primarily present in trading activities of resins & polymers, pharma chemicals & solvents and PVC pipes & fittings. The compa